Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24456549 | 0.89 | ALDH1A1 (0.50) | ALDH1A1NPC1MEN1KMT2AMAPT | |
| SCHEMBL13119145 | 0.84 | ALDH1A1 (0.41) | ALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL15337692 | 0.82 | ALDH1A1 (0.58) | ALDH1A1NPC1MEN1KMT2APHGDH | |
| SCHEMBL12450224 | 0.82 | GNAI3 (0.51) | ALDH1A1NPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8486131 | 0.82 | EPHX2 (0.44) | ALDH1A1NPC1KDM4EL3MBTL1 | |
| SCHEMBL18330367 | 0.81 | ALDH1A1 (0.56) | ALDH1A1NPC1MEN1KMT2APHGDH | |
| SCHEMBL24098153 | 0.81 | EPHX2 (0.40) | ALDH1A1NPC1MEN1KMT2AKDM4E | |
| SCHEMBL3930486 | 0.81 | L3MBTL1 (0.50) | ALDH1A1NPC1MEN1KMT2AMAPT | |
| SCHEMBL20232927 | 0.81 | NPC1 (0.67) | ALDH1A1NPC1MEN1KMT2APHGDH | |
| SCHEMBL23698639 | 0.79 | NCF1 (0.44) | ALDH1A1NPC1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| EP-3922632-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | GILEAD SCIENCES, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
| US-8748435-B2 | Pyrazolo pyrimidine derivatives | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748435-B2 | Pyrazolo pyrimidine derivatives | NOVARTIS AG (CH) | 2014-06-10 | — | — | US | disclosed |
| WO-2013155223-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| WO-2009074789-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, HIPK2 | ALDH1A1 3852/4885NPC1 2549/4885MEN1 3081/4885 |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 361/4885NPC1 155/4885MEN1 2558/4885 |
| US-20120252778-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | THPO, P2RX3, P2RX5 | ALDH1A1 2493/4885NPC1 4052/4885MEN1 4318/4885 |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | ALDH1A1 3852/4885NPC1 2549/4885MEN1 3081/4885 |
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885NPC1 2113/4885MEN1 2804/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | ALDH1A1 3852/4885NPC1 2549/4885MEN1 3081/4885 |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885NPC1 2113/4885MEN1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.